Publications by authors named "Eleana Kouroukli"
Background: Pulmonary exacerbations (PEx), pathogens colonizing the respiratory tract, and patients' age are associated with progressive worsening of lung function among patients with cystic fibrosis (CF). However, the effect of these factors on longitudinal changes of Lung Clearance Index (LCI) remains unclear.
Aim: To assess the role of age, different types of bronchial infection, and PEx on LCI deterioration.
Background: Adherence to pulmonary medication is pivotal in delaying the progression of lung disease in cystic fibrosis (CF). Further exploring the consequences of poor adherence and its impact on disease severity may be valuable to personalize CF treatment strategy.
Aim: To evaluate indicators of disease severity among children and adults with CF and investigate which of them are related to pulmonary medication adherence.
Article Synopsis
- The study evaluated how well teenagers and adults with cystic fibrosis (CF) adhered to inhaled therapies over four years and examined the impact of adherence on health outcomes.
- Results indicated that the average medication possession ratio was 0.75, with 43.4% of participants showing consistent adherence; those with stable adherence had significantly better medication management and weight outcomes.
- The findings suggest that better adherence is linked to higher patient weight, and the authors call for further research to understand the relationship between adherence and health in CF patients.
Novel targeted treatments for Cystic Fibrosis give rise to new hope for an ever-growing number of CF patients with various mutations. However, very little evidence and guidelines exist to steer clinical decisions regarding patients whose illness takes an unexpected course. In such cases, the benefits and risks of discontinuing these treatments must be carefully and individually weighed, since their long-term effects remain mainly uncharted territory.
View Article and Find Full Text PDFBackground: Inhaled Corticosteroids (ICS) are the cornerstone of asthma management in pediatric patients. However, in some cases, asthma is not adequately controlled on ICS alone. Long-acting beta-agonists (LABA) are one of the available additional therapies but their use has rarely been studied among children younger than 5 years.
View Article and Find Full Text PDFIntroduction: Asthma is the most common chronic respiratory disease in children and inhaled corticosteroids (ICS) constitute the first line of treatment for these patients. However, the potential growth-inhibiting effect of ICS has often been a cause of concern for both caregivers as well as physicians, and there still remains conflict regarding their safety profile.
Objective: To assess whether the administration of ICS in low or medium doses is associated with height reduction in prepubertal children.